Gabriël Jacobs was trained as general adult psychiatrist and clinical pharmacologist at the Leiden University Medical Centre (LUMC) and CHDR from 2006 to 2012. During the same period, he conducted his PhD research at CHDR on the clinical pharmacology of various challenge tests to quantify hypothalamus-pituitary-adrenal (HPA) axis function. Following his training, he worked as consultant psychiatrist in general hospital psychiatry/psychosomatic medicine at the VU medical centre in Amsterdam and research physician at CHDR. In 2016 he joined CHDR as research director and is currently attached to the department of psychiatry of the LUMC as consultant psychiatrist. In addition, he contributes to psychopharmacology education for trainees in psychiatry and clinical pharmacology, textbooks on various topics in psychopharmacology and Dutch national guidelines related to psychiatric patient care. Scientifically, he primarily focuses on strategies to translate findings from early phase proof-of-concept/proof-of-mechanism trials with novel compounds in healthy volunteers and high-risk healthy populations to patients suffering from anxiety and mood disorders. In this process, he is interested in developing innovative methodologies to measure both CNS and non-CNS drug effects in patients with psychiatric illness.
Gabriel JacobsResearch Director Psychiatry
|T:||+31 (0)71 524 64 22|